New Anti-HIV Protease Inhibitors Provide More Treatment Options

AIDS Patient Care and STDs

Volumn 17, Issue 11, 2003, Pages 551-564

  Nadler, Jeffrey ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Specialty Care Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLESTEROL; DARUNAVIR; DIDANOSINE; EFAVIRENZ; GSK 433908; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOOD; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; IC 50; JAUNDICE; LIPID BLOOD LEVEL; RASH; SCLERA DISEASE; TREATMENT OUTCOME; VERTIGO;

DRUG DESIGN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 0344823769     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729103322555944     Document Type: Article

References (70)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infecfion. N Engl J Med 1998;338:853-860.
2. US Department of Health and Human Services and the Henry J. Kaiser Family Foundation Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, D.C.: US Department of Health and Human Services; February 4, 2002.
3. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235.
4. Rosenbach KA, Allison R, Nadler JP. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis 2002;34:686-692.
5. Lichtenstein KA, Ward DJ, Moorman AC, et al., for the HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-1398.
6. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-1748.
7. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-111.
8. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-113.
9. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998;63:453-664.
10. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998;42: 2784-2791.
11. Sale M, Sadler BM, Stein DS. Pharmacokinetic Modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46:746-754.
12. Qazi NA, Morlese JF, Pozniak AL. Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother 2002;3: 315-327.
13. Bertz R, Foit C, Ye X, et al. Pharmacokinetics of once-daily vs twice-daily Kaletra (lopinavir/ritonavir) in HIV+ subjects [abstract 126]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002; Seattle, WA.
14. Eron JJ, Bernstein B, King M, et al. Once-daily vs. twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48-week follow-up [abstract 409-W]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002; Seattle, WA.
15. Feinberg J, Eron J, Bernstein J. Once-daily vs. twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 72 week follow-up [abstract TuPeB4445]. In: Program and Abstracts of the XIV International AIDS Conference, July 7-12, 2002; Barcelona, Spain.
16. 50 (IQ) after missed dose shows Agenerase advantage [abstract 352]. In: Program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, July 8-11, 2001; Buenos Aires, Argentina.
17. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999;179:1116-1123.
18. Schapiro JM, Winters MA, Stewart F, De Pascatis CR, Bassetti M, Bassetti D. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124: 1039-1050.
19. Gatti G, Pontali E, Boni S, De Pascalis CR, Bassetti M, Bassetti D. The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children. HIV Med 2002;3:125-128.
20. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19:708-712.
21. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000; 14:1333-1339.
22. Fletcher CV, Kakuda TN, Anderson PL, et al. Viral dynamics of concentration-targeted vs standard dose therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV) [abstract 322]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-29, 1999; San Francisco, CA.
23. Piscitelli SC, Metcalf J, Hoetelmans R, Falloon J. The relative inhibitory quotient (RIQ): A method for predicting response to protease inhibitors [abstract 164]. In: Program and Abstracts of the 8th European Congress on Clinical Aspects and Treatment of HIV Infection, October 28-31, 2001; Athens, Greece.
24. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002;46:3907-3916.
25. Danner S, Brun S, Sylte J, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72 week safety/efficacy evaluation and phenotypic/genotypic breakpoints in multiple PI experienced patients [abstract 1-1925]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001; Chicago, IL.
26. Hsu R, Bellman PC. The combination of ritonavir and amprenavir in salvage regimens overcomes clinically multiple-drug resistant HIV [abstract WePeB4204]. In: Program and Abstracts of the XIII International AIDS Conference, July 9-14, 2000; Durban, South Africa.
27. McComsey GA, Chu A. Effect of ritonavir-boosted protease inhibitor (PI) regimens on lipid profiles [abstract ThPeB7319]. In: Program and Abstracts of the XIV International AIDS Conference, July 7-12, 2002; Barcelona, Spain.
28. Palella F, Chmiel J, Moorman A, Chan C, Holmberg S. Correlates of durable treatment success among long-term highly active antiretroviral (HAART) recipients in the HIV outpatient study (HOPS) [abstract 7581. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections: January 30-February 2, 2000; San Francisco, CA.
29. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-868.
30. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-953.
31. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.
32. Hardy D, Pedneault L, Mustafa N, et al. A pilot study of abacavir + amprenavir + efavirenz + adefovir in PI- and NRTI-experienced HIV-infected subjects [abstract WePeB4177]. In: Program and Abstracts of the XIII International AIDS Conference, July 9-14, 2000; Durban, South Africa.
33. sgc, indinavir (IDV) or nelfinavir (NFV) in combination with amprenavir (APV), abacavir (ABC), efavirenz (EFZ) & adefovir (ADV) in patients (Pts) with protease inhibitor (PI) failure [abstract LB7]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000; San Francisco, CA.
34. Masur H, Falloon J, Thomas D, et al. Durability of abacavir/amprenavir/efavirenz combination salvage therapy-Preliminary 48-week response [abstract 206]. In: Program and Abstracts of the 7th European Congress on Clinical Aspects and Treatment of HIV Infection, October 23-27, 1999; Lisbon, Portugal.
35. Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr 2000;23:221-226.
36. Plosker GL, Perry CM, Goa KL. Efavirenz: A pharmacoeconomic review of its use in HIV infection. Pharmacoeconomics 2001;19:421-436.
37. Robbins G, Shafer R, Smeaton L, et al. Antiretroviral strategies in naive HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384) [abstract LbOr20A]. In: Program and Abstracts of the XIV International AIDS Conference, July 7-12, 2002; Barcelona, Spain.
38. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-1873.
39. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
40. Pantaleo G, Sanne I, Cahn P, et al. Atazanavir (BMS-232632): 48-week safety and efficacy vs nelfinavir, each in combination with stavudine and lamivudine, in treatment-naive, HIV-positive subjects (AI424-008) [abstract 223; oral presentation 11]. In: Program and Abstracts of the 8th European Congress on Clinical Aspects and Treatment of HIV Infection, October 28-31, 2001; Athens, Greece.
41. Haas DW, Zala C, Schrader S, Thiry A, McGovern R, Schnittman S. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (Trial A1424-009, week 48) [abstract 42]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002; Seattle, WA.
42. Colonno R, Rose R, Cianci C, et al. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with an I50L substitution in HIV protease [abstract 597]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, MA.
43. Haubrich RH, Kemper CA, Hellmann NS, et al., and the California Collaborative Treatment Group. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: A prospective cohort analysis. AIDS 2002;16:F33-40.
44. Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000;74: 4414-4419.
45. Squires KE, Thiry A, Giordano M, for the AI424-034 International Study Team. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV + 3TC: comparison of antiviral efficacy and safety through week 24 (AI424-034) [abstract H-1076]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2000; San Diego, CA.
46. Murphy R, Thiry A, Mancini M, Pokrovsky V, Rozenbaum W. Twelve weeks of atazanavir treatment reverses nelfinavir-associated hyperlipidaemia: Results from BMS AI424-044 [abstract 15]. Antivir Ther 2002;7:L10.
47. Sension M, Thiry A, Giordano M, for the AI424-034 International Study Team. Absence of insulin resistance through week 24 with atazanavir once-daily and efavirenz once-daily, each with fixed-dose zidovudine plus lamivudine [abstract 36]. Antivir Ther 2002;7:L26.
48. Agarwala S, Russo R, Mummaneni V, Randall D, Geraldes M, O'Mara E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects [abstract H-1716]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002; San Diego, CA.
49. O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple-dose pharmacokinetic, food effect, and drug interaction studies in healthy subjects [abstract 504]. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000; Toronto, Ontario, Canada.
50. Sanne I, Piliero P, Wood R, et al. Safety and antiviral efficacy of a novel once-daily HIV-1 protease inhibitor, BMS-232632: Preliminary results from a phase II clinical trial [abstract 672]. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000; Toronto, Ontario, Canada.
51. Nadler JP, Rodriguez-French A, Miller J, Wannamaker P. The NEAT study: GW433908 efficacy and safety in ART-naive subjects, final 48-week analysis [abstract 1771. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14; 2003; Boston, MA.
52. Falcoz C, Jenkins JM, Bye C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol 2002;42:887-898.
53. Elston R, Randall S, Xu F, et al. High plasma trough levels favour selection of the I50V mutation pathway during development of APV resistance. In: Posters of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy; April 2-4, 2001; Noordwijk, The Netherlands. Poster 5.1.
54. MacManus S, Yates PJ, White S, Richards N, Snowden W. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen [abstract 598]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, MA.
55. Prado JG, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002;16:1009-1017.
56. Parkin NT, Chappey C, Petropoulos CJ. Mutations in HIV-1 protease associated with resistance to amprenavir contribute towards phenotypic resistance to lopinavir [abstract 24]. Antivir Ther 2002;7:S23.
57. Elston R, Wolfram J, Richards N, Tisdale M, Kleim JP, Snowden W. Differential impact of specific HIV protease on phenotypic susceptibility to amprenavir and lopinavir [abstract 71]. Antivir Ther 2001;6(Suppl 1):53.
58. Paulsen D, Liao Q, Fusco G, St. Clair M, Shaeffer M, Ross L. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses 2002;18:1011-1019.
59. Kempf D, Bernstein B, King M, et al. Comparison of the emergence of genotypic resistance over 48-weeks of therapy with ABT-378/R (Kaletra®) or nelfinavir plus d4T/3TC [abstract 129]. In: Program and Abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment, July 8-11, 2001; Buenos Aires, Argentina.
60. Walmsley S, Bernstein B, King M, et al, for the M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046.
61. Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Med 2003;4:38-47.
62. Gomes P, Diogo I, Gonçalves MF, et al. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G [abstract 46]. In: Programs and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002; Seattle, WA.
63. Murphy R, Brun S, King M, et al. Lopinavir/ritonavir (Kaletra) in antiretroviral naive HIV + patients: 4 year follow-up [abstract H-165]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002; San Diego, CA.
64. Kempf D, Brun S, Rode R, et al. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients [abstract 89]. Antivir Ther 2000;5(Suppl 3):70.
65. Gathe J, Kohlbrenner VM, Pierone G, et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52 [abstract 179]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, MA.
66. Slater L, Farthing C, Jayaweera J, et al. Safety and efficacy of tipranavir (TPV), a novel non-peptide protease inhibitor, plus ritonavir (RTV), in PI-failure patients [abstract LB-15]. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001; Chicago, IL.
67. Cooper D, Hall D, Jayaweera D, et al. Baseline phenotypic susceptibility to tipranavir/ritonavir (TPV/r) is retained in isolates from patients with multiple-protease inhibitor (PI) experience (BI 1182.52). In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, MA, Abst 596.
68. McCallister S, Neubacher D, Verbiest W, Mayers DL. Susceptibility profile of tipranavir at baseline and subsequent virological response in a cohort of patients with multiple protease inhibitor-failure [abstract 127]. Antivir Ther 2002;7:S106.
69. Arasteh K, Clumeck N, Pozniak A, et al. First clinical results on antiretroviral activity, pharmacokinetics, and safety of TMC114, an HIV-1 protease inhibitor, in multiple PI-experienced patients [abstract 8]. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, MA.
70. De Meyer S, Azijn H, Van Ginderen M, De Baere I, Pauwels R, de Béthune M-P. In vitro selection experiments demonstrate an increased genetic barrier to resistance developments to TMC114 as compared with currently licensed protease inhibitors [abstract 5]. Antivir Ther 2002;7:S5.